Clinical trial
Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage…
NCT00217542 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00217542 |
|---|---|
| Title | Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery |
| Official title | A Phase 1 Study of 5-azacitidine in Combination With Interferon-Alfa 2B in Unresectable or Metastatic Melanoma and Renal Cell Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Recurrent Melanoma, Recurrent Renal Cell Cancer, Stage III Melanoma, Stage IV Melanoma, Stage IV Renal Cell Cancer |
| Intervention type | Biological, Drug |
| Interventions | recombinant interferon alfa-2b, amifostine/azacitidine |
| Enrollment | 42 |
| Start date | Jul 1, 2005 |
| Primary completion | Jul 1, 2008 |
| First posted | Sep 22, 2005 |
| Last update posted | May 3, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: